Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytogen Corporation has presented clinical data demonstrating that a high level of prostate-specific membrane antigen, or PSMA, in prostate tissue is a strong predictor of prostate cancer recurrence.
Subscribe to our email newsletter
The data was presented at the 101st American Urological Association (AUA) annual meeting held in Atlanta, Georgia.
In the study, independent investigators from Ulm, Germany, and Boston, Massachusetts, analyzed PSMA expression by tissue microarray in 96 patients with either localized or metastatic prostate cancer who had undergone radical prostatectomy, or surgical removal of the prostate, as monotherapy.
Significant up-regulation of PSMA expression was noted in patients with metastatic disease as compared to those with localized prostate cancer, and in localized disease compared to benign prostate tissue.
High PSMA levels were associated with a significant increase in disease recurrence following therapy in univariate statistical analyses.
“There is a tremendous need for better prognostic markers in prostate cancer to assist in the identification of patients with aggressive forms of the disease who can potentially benefit from earlier and more intensive forms of treatment. The findings presented at AUA further support our belief in the importance of PSMA as an independent prostate cancer marker and important diagnostic and therapeutic target,” said Michael Becker, president and CEO of Cytogen.